Close

Prima BioMed Ltd (PBMD) Announces Positive Data from CAN-003 Phase II in Ovarian Cancer

May 26, 2015 7:56 AM EDT Send to a Friend
Prima BioMed Ltd (NASDAQ: PBMD) announced that the final CVac data from the Phase II CAN-003 ovarian cancer clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login